NUVB | Ticker Profile - Titan Protect

NUVB

Nuvation Bio Inc.

Healthcare · Biotechnology · NYQ

$4.82

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.7B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-79.00

Based on estimated future earnings — lower means cheaper

Rev Growth

+2,598.7%

Year-over-year revenue change

Profit Margin

-102.1%

How much profit the company keeps from each dollar of revenue

ROE

-39.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$12.00

+149% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 9 analysts covering this stock

About Nuvation Bio Inc.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

https://www.nuvationbio.com

Country: United States Employees: 307 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.696

Good returns relative to risk taken

Kelly Fraction

0.0296

Modest edge detected — smaller position warranted

Calmar Ratio

0.482

Drawdown risk outweighs the returns — higher risk profile

Annual Return

27.7%

Historical annualised return based on price data

Max Drawdown

-57.6%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.52

Significantly more volatile than the market

52W High

$9.75

51% below the year high

52W Low

$1.57

207% above the year low

Avg Volume

4,382,101

Average daily shares traded — higher means easier to buy and sell

Short Ratio

11.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

24.5%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.43

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

67.90

Heavy leverage — higher financial risk if revenues decline

Current Ratio

7.44

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

7.04

Like current ratio but excludes inventory — stricter test

Gross Margin

90.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

4.7%

Profit from core operations before interest and tax

Free Cash Flow

$-100,037,872

Negative — the business is spending more than it generates

Revenue (TTM)

$143M

Total revenue over the last 12 months

Net Income

$-145,994,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$20.00

Target Median

$12.00

Target Low

$7.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go